P53 Gene Mutations in Lymphoid Diseases and Their Possible Relevance to Drug Resistance

References

• Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature 1991; 351: 453–456
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Soussi T., Jonveaux P. p53 gene alterations in human hematological malignancies: a review. Nouv. Rev. Fr. Hematol. 1991; 33: 477–480
   PubMedGoogle Scholar
• Caron de Fromentel C., Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer 1992; 4: 1–15
   PubMed Web of Science ®Google Scholar
• Frebourg T., Friend S. H. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence?. Natl. Cancer Inst. 1993; 85: 1554–1557
   Google Scholar
• Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. New Engl. J. Med. 1993; 329: 1318–1327
   PubMed Web of Science ®Google Scholar
• Harris C. C. p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993; 262: 1980–1981
   PubMed Web of Science ®Google Scholar
• Milner J. Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 1984; 310: 143–145
   PubMed Web of Science ®Google Scholar
• Reich N. C., Levine A. J. Growth regulation of acellu-lar tumour antigen, p53, in nontransformed cells. Nature 1984; 308: 199–201
   PubMed Web of Science ®Google Scholar
• Danova M., Giordano M., Mazzini G., Riccardi A. Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk. Res. 1990; 14: 417–422
   PubMed Web of Science ®Google Scholar
• Rivas C. I., Wisniewski D., Strife A., Perez A., Lambck C., Bruno S., Darzynkiewicz D., Clarkson B. Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood 1992; 79: 1982–1986
   PubMed Web of Science ®Google Scholar
• Prokocimer M., Shaklai M., Bassat H. B., Wolf D., Goldfinger N., Rotter V. Expression of p53 in human leukemia and lymphoma. Blood 1986; 68: 113–118
   PubMed Web of Science ®Google Scholar
• Kastan M. B., Radin A. I., Kuerbitz S. J., Onyekwere O., Wolkow C. A., Civin C. I., Stone K. D., Woo T., Ravindranath Y., Craig R. W. Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res. 1991; 51: 4279–4286
   PubMed Web of Science ®Google Scholar
• Green D. R., Bissonnette R. P., Cotter T. G. Apoptosis and cancer. Principles & Practice of Oncol. 1994; 8: 1–14
   Google Scholar
• Williams G. T., Smith C. A., McCarthy N. J., Grimes E. A. Apoptosis: final control point in cell biology. Trends Cell Biol 1992; 2: 263–267
   PubMedGoogle Scholar
• Lowe S. W., Schmitt E. M., Smith S. W., Osborne B. A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–849
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Kinzler K. W. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Halevy O., Michalovitz D., Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990; 250: 113–116
   PubMed Web of Science ®Google Scholar
• Milner J., Medcalf E. A. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell. 1991; 65: 765–774
   PubMed Web of Science ®Google Scholar
• Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9: 1595–1602
   PubMed Web of Science ®Google Scholar
• Eliyahu D., Raz A., Gruss P., Givol D., Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984; 312: 646–649
   PubMed Web of Science ®Google Scholar
• Parada L. M., Land H., Weinberg R. A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 1984; 312: 649–654
   PubMed Web of Science ®Google Scholar
• Deffie A., Wu H., Reinke V., Lozano G. The tumor suppressor p53 regulates its own transcription. Mol. Cell. Biol 1993; 13: 3415–3423
   PubMed Web of Science ®Google Scholar
• Raycroft L., Wu H., Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-onco-gene. Science 1990; 249: 1049–1051
   PubMed Web of Science ®Google Scholar
• Kern S. E., Kinzler K. W., Bruskin A., Jarosz D., Friedman P., Privcs C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708–1711
   PubMed Web of Science ®Google Scholar
• Hupp T. R., Meek D. W., Midgley C. A., Lane D. P. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875–886
   PubMed Web of Science ®Google Scholar
• Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992; 255: 459–462
   PubMed Web of Science ®Google Scholar
• Seto E., Usheva A., Zambetti G. P., Momand J., Horikoshi N., Weinmann R., Levine A. J., Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. 1992; 89: 12028–12032
   PubMed Web of Science ®Google Scholar
• Mack D. H., Vartikar J., Pipas J. M., Laimins L. A. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 1993; 363: 281–283
   PubMed Web of Science ®Google Scholar
• Lane D. P., Crawford L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261–263
   PubMed Web of Science ®Google Scholar
• Linzer D. I. H., Levine A. J. Characterization of a 54K dalton cellular SV40 antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43–52
   PubMed Web of Science ®Google Scholar
• Howley P. M. Role of the human papillomaviruses in human cancer. Cancer Res. 1991; 51: 5019–5022
   PubMed Web of Science ®Google Scholar
• Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Park S., Bernard A., Morris J. F., Rauscher F. J., Hill D. E., Haber D. A. Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. 1993; 90: 5100–5104
   PubMed Web of Science ®Google Scholar
• Gaidano G., Ballerini P., Gong J. Z., Inghirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K., Hirai H., Ishikawa F., Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–1156
   PubMed Web of Science ®Google Scholar
• Felix C. A., D'Amico D., Mitsudomi T., Nau M. M., Li F. P., Fraumeni J. F., Cole D. E., McCalla J., Reaman G. H., Whang-Peng J., Knutsen T., Minna J. D., Poplack D. G. Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J. Clin. Invest. 1992; 90: 653–658
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jonveaux P., Quiquandon I., Preudhomme C., Lai J. L., Vanrumbeke M., Lousheux-Lefebvre M. H., Bauters F., Berger R., Kerchaert J. P. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia 1992; 6: 42–46
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Tanaka S., Nishigaki H., Taniwaki M., Yokota S., Horiike S., Takashima T., Seriu T., Nakagawa H., Fujii H., Shimazaki C., Okada H., Toguchida J., Ishizaki K., Abe T., Kashima K. p53 gene mutations and loss of a chromosome 17p in Philadelphia chromosome (Ph1)-positive acute leukemia. (1993). Leukemia 1993; 10: 1547–1551
   Google Scholar
• Bhatia K. G., Gutierrez M. I., Huppi K., Siwarski D., Magrath I. T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res. 1992; 52: 4273–4276
   PubMed Web of Science ®Google Scholar
• Ichikawa A., Hott T., Takagi N., Tsushita K., Kinoshita T., Nagai H., Murakami Y., Hayashi K., Saito H. Mutations of p53 and their relation to disease progression in B-cell lymphoma. Blood 1992; 10: 2701–2707
   Google Scholar
• El Rouby S., Bayona W., Pisharody S. M., Newcomb E. W. p53 mutations in B-cell chronic lymphocytic leukemia. Curr. Topics Microbiol. Immunol. 1992; 182: 313–317
   PubMedGoogle Scholar
• Fenaux P., Preudhomme C., Lai J. L., Quiquandon I., Jonveaux P., Vanrumbeke M., Sartiaux C., Morel P., Loucheux-Lefebvre M. H., Bauters F., Berger R., Kerckaert J. P. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246–250
   PubMed Web of Science ®Google Scholar
• El Rouby S., Thomas A., Costin D., Rosenberg C. R., Potmesil M., Silber R., Newcomb E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Gaidano G., Newcomb E. W., Gong J. Z., Tassi V., Neri A., Cortelezzi A., Calori R., Baldini L., Dalla-Favera R. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Amer. J. Pathol. 1994; 144: 1312–1319
   PubMed Web of Science ®Google Scholar
• Mazars G. R., Portier M., Zhang X. G., Jourdan M., Bataille R., Theillet C., Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 1015–1018
   PubMed Web of Science ®Google Scholar
• Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128–135
   PubMed Web of Science ®Google Scholar
• Willems P. M. W., Kuypers A. W. H. M., Meijerink J. P. P., Holdrinet R. S. G., Mensink J. B. M. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees. Leukemia 1993; 7: 986–991
   PubMed Web of Science ®Google Scholar
• Jonveaux P., Berger R. Infrequent mutations in the p53 gene in primary human T-cell acute lymphoblastic leukemia. Leukemia 1991; 10: 839–840
   Google Scholar
• Nagai H., Kinoshita T., Imamura J., Murakami Y., Hayashi K., Mukai K., Ikeda S., Tobinai K., Saito H., Shimoyama M., Shimotohno K. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn. J. Cancer Res. 1991; 82: 1421–1427
   PubMedGoogle Scholar
• Sugito S., Yamato K., Sameshima Y., Yokota J., Yano S., Miyoshi I. Adult T-cell leukemia: structures and expression of the p53 gene. Int. J. Cancer 1991; 49: 880–885
   PubMed Web of Science ®Google Scholar
• Sakashita A., Hattori T., Miller C. W., Suzushima H., Asou N., Takatsuki K., Koeffler H. P. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992; 79: 477–480
   PubMed Web of Science ®Google Scholar
• Cesarman E., Chadburn A., Inghirami G., Gaidano G., Knowles D. M. Structural and functional analysis of oncogenes and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood 1992; 80: 3205–3216
   PubMed Web of Science ®Google Scholar
• Yamato K., Oka T., Hiroi M., Iwahara Y., Sugito S., Tsuchida N., Miyoshi I. Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-1-infected cells. Jpn. J. Cancer Res. 1993; 84: 4–8
   PubMedGoogle Scholar
• Slingerland J. M., Minden M. D., Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood 1991; 77: 1500–1507
   PubMed Web of Science ®Google Scholar
• Fenaux P., Jonveaux P., Quiquandon I., Lai J. L., Pignon J. M., Loucheux-Lefebre M. H., Bauters F., Berger R., Kerckaert J. P. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78: 1652–1657
   PubMed Web of Science ®Google Scholar
• Zhang W., Hu G., Estey E., Hester J., Deisseroth A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992; 7: 1645–1647
   PubMed Web of Science ®Google Scholar
• Schutte J., Opalka B., Becher R., Bardenheuer W., Szymanski S., Lux A., Seeber S. Analysis of the p53 gene in patients with isochrosome 17q and Ph1-positive or negative myeloid leukemia. Leukemia Res. 1993; 17: 533–539
   PubMed Web of Science ®Google Scholar
• Ahuja H., Bar-Eli M., Arlin Z., Advani S., Allen S. L., Goldman J., Snyder D., Foti A., Cline M. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest. 1991; 87: 2042–2047
   PubMed Web of Science ®Google Scholar
• Feinstein E., Cimino G., Gale R. P., Alimena G., Berthier R., Kishi K., Goldman J., Zaccaria A., Berrebi A., Canaani E. p53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad. Sci. 1991; 88: 6293–6297
   PubMed Web of Science ®Google Scholar
• Foti A., Ahuja H. G., Allen S. L., Koduru P., Schuster M. W., Schulman P., Bar-Eli M., Cline M. J. Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood 1991; 77: 2441–2444
   PubMed Web of Science ®Google Scholar
• Nakai H., Misawa S., Toguchida J., Yandell D. W., Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia: especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res. 1992; 52: 6588–6593
   PubMed Web of Science ®Google Scholar
• Jonveaux P. H., Fenaux P., Quiquandon I., Pignon J. M., Lai J. L., Loucheux-Lefebvre M. H., Goossens C., Bauters F., Berger R. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 1991; 6: 2243–2247
   PubMed Web of Science ®Google Scholar
• Rideout W. M., Coetzee G. A., Olumi A. F., Jones P. A. 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990; 249: 1288–1290
   PubMed Web of Science ®Google Scholar
• Dobner H., Fischer K., Cabot G. F., Hansen K., Pilz T., Diebl D., Stilgenbauer S., Benner A., Bentz M., Lichter P. Incidence and prognostic significance of recurring chromosome abnormalities in chronic B-cell leukemias, an interphase cytogenetic analysis. Blood (suppl, abstract) 1994; 84: 2238
   Google Scholar
• Goldstein L. J., Galski H., Fojo A., Willingham M., Shinn L. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M., Lieber M., Cossman J., Gottesman M., Pastan I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 1989; 81: 116–124
   PubMed Web of Science ®Google Scholar
• Noonan K. E., Beck C., Holzmayer T. A., Chin J. E., Wunder J. S., Andrulis I. L., Gazdar A. F., Willman C. L., Griffith B., Von Hoff D. D., Roninson I. B. Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. 1990; 87: 7160–7164
   PubMed Web of Science ®Google Scholar
• Herweijer H., Sonneveld P., Baas F., Nooter K. Expression of mdrl and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.7. Natl. Cancer Inst. 1990; 82: 1133–1140
   Google Scholar
• Shustik C., Groulx N., Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br. J. Haematol. 1991; 79: 50–56
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Nooter K., Burghouts J. T. M., Herweijer H., Adriaansen H. J., van Dongen J. J. M. High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496–1500
   PubMed Web of Science ®Google Scholar
• Ludescher C., Hilbe W., Eisterer W., Preuss E., Huber C., Golwald M., Hofmann J., Thaler J. Activity of P-gly-coprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst. 1993; 85: 1751–1758
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-de-oxyadenosine and 9-B-arabinosyl-2-fluoradenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Lowe S. W., Ruley H. E., Jacks T., Houseman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–967
   PubMed Web of Science ®Google Scholar
• Walton M. I., Whysong D., O'Connor P. M., Hockenbery D., Korsmeyer S. J., Kohn K. W. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 1993; 53: 1853–1861
   PubMed Web of Science ®Google Scholar
• Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879–886
   PubMed Web of Science ®Google Scholar
• Bissonnette R. P., Echeverri F., Mahboubi A., Green D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 358: 552–556
   Web of Science ®Google Scholar
• Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J. C. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820–1828
   PubMed Web of Science ®Google Scholar
• Chiou S. K., Rao L., White E. Bcl-2 blocks p53-de-pendent apoptosis. Mol. Cell. Biol 1994; 14: 2556–2563
   PubMed Web of Science ®Google Scholar
• Reed J. C., Stein C., Subasinghe C., Haldar S., Croce C. M., Yum S., Cohen J. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemia cell growth and survival: comparison of phosphodiester and phosphorothioate oliogodeoxynucleotides. Cancer Res. 1990; 50: 6565–6570
   PubMed Web of Science ®Google Scholar
• Bi S., Lanza F., Goldman J. M. The involvement of “tumor suppressor” p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res. 1994; 54: 582–586
   PubMed Web of Science ®Google Scholar
• Oltval Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell 1993; 74: 609–619
   PubMed Web of Science ®Google Scholar
• Yin X.-M., Oltval Z. N., Korsmeyer S. J. BHI and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 1994; 369: 321–323
   PubMed Web of Science ®Google Scholar
• Ginsberg A. M., Raffeld M., Cossman J. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood 1991; 77: 833–840
   PubMed Web of Science ®Google Scholar
• Kornblau S. M., Chen N., del Giglio A., O'Brien S., Deisseroth A. B. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Res. 1994; 54: 242–246
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–440
   PubMed Web of Science ®Google Scholar
• Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753–756
   PubMed Web of Science ®Google Scholar